TissGeneSummary for ORAI1 |
Gene summary |
Basic gene information | Gene symbol | ORAI1 |
Gene name | ORAI calcium release-activated calcium modulator 1 | |
Synonyms | CRACM1|IMD9|ORAT1|TAM2|TMEM142A | |
Cytomap | UCSC genome browser: 12q24.31 | |
Type of gene | protein-coding | |
RefGenes | NM_032790.3, | |
Description | calcium release-activated calcium channel protein 1calcium release-activated calcium modulator 1protein orai-1transmembrane protein 142A | |
Modification date | 20141221 | |
dbXrefs | MIM : 610277 | |
HGNC : HGNC | ||
HPRD : 08599 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ORAI1 | |
BioGPS: 84876 | ||
Pathway | NCI Pathway Interaction Database: ORAI1 | |
KEGG: ORAI1 | ||
REACTOME: ORAI1 | ||
Pathway Commons: ORAI1 | ||
Context | iHOP: ORAI1 | |
ligand binding site mutation search in PubMed: ORAI1 | ||
UCL Cancer Institute: ORAI1 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | OvarySkin | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | OVSKCM | |
Reference showing the relevant tissue of ORAI1 | ||
Description by TissGene annotations | Have significant anti-correlated miRNA TissgsLTS |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID | GO:0051928 | positive regulation of calcium ion transport | 16645049 | GO:0051928 | positive regulation of calcium ion transport | 16645049 |
Top |
TissGeneExp for ORAI1 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for ORAI1 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
UCS | hsa-miR-106b-5p | MIMAT0000680 | 0.029 | -0.29 | 56 |
LUAD | hsa-miR-20b-5p | MIMAT0001413 | 0.0054 | -0.36 | 60 |
Top |
TissGeneMut for ORAI1 |
TissGeneSNV for ORAI1 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.H288Q | HNSC | 1 |
p.A238T | LUAD | 1 |
p.V255I | UCEC | 1 |
p.P295L | SKCM | 1 |
p.G185D | GBM | 1 |
p.M106V | LAML | 1 |
p.H290Q | HNSC | 1 |
p.A113T | STAD | 1 |
p.G247S | HNSC | 1 |
p.T214N | HNSC | 1 |
p.G249S | HNSC | 1 |
p.A282V | GBM | 1 |
p.E277D | COAD | 1 |
p.A237V | CHOL | 1 |
p.S50C | LUAD | 1 |
p.V226F | ESCA | 1 |
p.R169L | LUAD | 1 |
p.S181F | SKCM | 1 |
p.A111T | STAD | 1 |
p.P44A | LIHC | 1 |
p.S48C | LUAD | 1 |
p.R270Q | UCEC | 1 |
p.A279S | THYM | 1 |
p.A240T | LUAD | 1 |
p.R268Q | UCEC | 1 |
p.S159L | UCEC | 1 |
Top |
TissGeneCNV for ORAI1 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ORAI1 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | FusionScan | UCEC | TCGA-D1-A3DG-01A | TMEM120B-ORAI1 | Out-of-Frame | chr12:122199644 | chr12:122078946 |
Top |
TissGeneNet for ORAI1 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ORAI1 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ORAI1 |
TissGeneDrug for ORAI1 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ORAI1 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0019693 | HIV Infections | 6 | BeFree |
umls:C0006142 | Malignant neoplasm of breast | 5 | BeFree |
umls:C0085110 | Severe Combined Immunodeficiency | 5 | BeFree |
umls:C0678222 | Breast Carcinoma | 5 | BeFree |
umls:C0017636 | Glioblastoma | 3 | BeFree |
umls:C0025202 | melanoma | 3 | BeFree |
umls:C0020538 | Hypertensive disease | 2 | BeFree,CTD_human |
umls:C0021051 | Immunologic Deficiency Syndromes | 2 | BeFree |
umls:C0027627 | Neoplasm Metastasis | 2 | BeFree,LHGDN |
umls:C0376358 | Malignant neoplasm of prostate | 2 | BeFree |
umls:C0392525 | Nephrolithiasis | 2 | BeFree |
umls:C0410207 | Tubular Aggregate Myopathy | 2 | BeFree,ORPHANET |
umls:C0600139 | Prostate carcinoma | 2 | BeFree |
umls:C1621958 | Glioblastoma Multiforme | 2 | BeFree |
umls:C1706004 | Anhydrotic Ectodermal Dysplasias | 2 | BeFree |
umls:C0004364 | Autoimmune Diseases | 1 | BeFree |
umls:C0011615 | Dermatitis, Atopic | 1 | BeFree |
umls:C0013595 | Eczema | 1 | BeFree |
umls:C0017638 | Glioma | 1 | BeFree |
umls:C0018133 | Graft-vs-Host Disease | 1 | BeFree |
umls:C0024314 | Lymphoproliferative Disorders | 1 | BeFree |
umls:C0026691 | Mucocutaneous Lymph Node Syndrome | 1 | BeFree |
umls:C0026827 | Muscle hypotonia | 1 | BeFree |
umls:C0026850 | Muscular Dystrophy | 1 | BeFree |
umls:C0038013 | Ankylosing spondylitis | 1 | BeFree |
umls:C0041341 | Tuberous Sclerosis | 1 | BeFree |
umls:C0042769 | Virus Diseases | 1 | BeFree |
umls:C0279626 | Squamous cell carcinoma of esophagus | 1 | BeFree |
umls:C0524702 | Pulmonary Thromboembolisms | 1 | BeFree |
umls:C0596263 | Carcinogenesis | 1 | BeFree |
umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
umls:C0858252 | Breast adenocarcinoma | 1 | BeFree |
umls:C1458155 | Mammary Neoplasms | 1 | BeFree |
umls:C1708565 | Invasive Skin Melanoma | 1 | BeFree |
umls:C1709246 | Non-Neoplastic Disorder | 1 | BeFree |
umls:C1846064 | Recurrent infections (sinusitis and bacterial pneumonia and meningitis) | 1 | BeFree |
umls:C2748557 | Immune dysfunction with T-cell inactivation due to calcium entry defect 2 | 1 | BeFree |
umls:C2748568 | Immune dysfunction with T-cell inactivation due to calcium entry defect 1 | 1 | CLINVAR,CTD_human,ORPHANET,UNIPROT |
umls:C4014557 | MYOPATHY, TUBULAR AGGREGATE, 2 | 1 | UNIPROT |